Cervical adenocarcinoma: Moving towards better prevention

Vaccine

Volumn 29, Issue 49, 2011, Pages 9148-9158

  Seoud, Muhieddine ^a   Tjalma, Wiebren A A ^b   Ronsse, Veerle ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adenocarcinoma; Cross protection; HPV testing; Human papillomavirus; Prophylactic vaccination; Screening

Indexed keywords

WART VIRUS VACCINE;

CANCER CLASSIFICATION; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CERVICAL ADENOCARCINOMA; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFICACY; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; INFECTION CONTROL; LYMPH NODE METASTASIS; MASS SCREENING; MULTIPARA; OBESITY; ORAL CONTRACEPTION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SECONDARY PREVENTION; SEROPREVALENCE; SEXUAL TRANSMISSION; SEXUALITY; SMOKING; SQUAMOUS CELL CARCINOMA; TREND STUDY; TUMOR RECURRENCE; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 82555205237     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.115     Document Type: Review

References (141)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
2. World Health Organization. WHO/ICO information on centre on human papillomavirus virus and cervical cancer; 2010. Available at: [accessed July 2011]. http://apps.who.int/hpvcentre/statistics/dynamic/ico/DataQuerySelect.cfm.
3. Arbyn M., Anttila A., Jordan J., et al. European guidelines for quality assurance in cervical cancer screening 2008, European Communities, Luxembourg. 2nd ed.
4. Gakidou E., Nordhagen S., Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 2008, 5(6):e132.
5. Vizcaino A.P., Moreno V., Bosch F.X., et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000, 86(3):429-435.
6. Mathew A., George P.S. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix - worldwide. Asian Pac J Cancer Prev 2009, 10(4):645-650.
7. Smith H.O., Tiffany M.F., Qualls C.R., Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol 2000, 78(2):97-105.
8. Vinh-Hung V., Bourgain C., Vlastos G., et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer 2007, 7:164-176.
9. Vizcaino A.P., Moreno V., Bosch F.X., Munoz N., Barros-Dios X.M., Parkin D.M. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998, 75(4):536-545.
10. Parkin D.M., Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3):S11-S25.
11. American Cancer Society. What is cervical cancer? 2009. Available at: [accessed July 2011]. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_is_cervical_cancer_8.asp.
12. Bosch F.X., Burchell A.N., Schiffman M., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl. 10):K1-K16.
13. Tjalma W, on behalf of the HERACLES/SCALEstudy group. Human papillomavirus type distribution in cervical neoplasia: results from two parallel epidemiological studies in women with high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. In: IPvC 2010. Montreal, Canada, 8 February 2010. Abstract.
14. Burd E.M. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003, 16(1):1-17.
15. Hayes M.M., Matisic J.P., Chen C.J., et al. Cytological aspects of uterine cervical adenocarcinoma, adenosquamous carcinoma and combined adenocarcinoma-squamous carcinoma: appraisal of diagnostic criteria for in situ versus invasive lesions. Cytopathology 1997, 8(6):397-408.
16. Bertrand M., Lickrish G.M., Colgan T.J. The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment. Am J Obstet Gynecol 1987, 157(1):21-25.
17. Jaworski R.C. Endocervical glandular dysplasia, adenocarcinoma in situ, and early invasive (microinvasive) adenocarcinoma of the uterine cervix. Semin Diagn Pathol 1990, 7(3):190-204.
18. Boon M.E., Baak J.P., Kurver P.J., Overdiep S.H., Verdonk G.W. Adenocarcinoma in situ of the cervix: an underdiagnosed lesion. Cancer 1981, 48(3):768-773.
19. Ostor A., Rome R., Quinn M. Microinvasive adenocarcinoma of the cervix: a clinicopathologic study of 77 women. Obstet Gynecol 1997, 89(1):88-93.
20. Lee K.R. Symposium part 4: should pathologists diagnose endocervical preneoplastic lesions " less than" adenocarcinoma in situ? Counterpoint. Int J Gynecol Pathol 2003, 22(1):22-24.
21. Zaino R.J. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 2002, 21(4):314-326.
22. Gunnell A.S., Ylitalo N., Sandin S., Sparen P., Adami H.O., Ripatti S. A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev 2007, 16(12):2641-2648.
23. Hirschowitz L., Sen C., Murdoch J. Primary endometrioid adenocarcinoma of the cervix with widespread squamous metaplasia - a potential diagnostic pitfall. Diagn Pathol 2007, 2:40.
24. McCluggage W.G., Sumathi V.P., McBride H.A., Patterson A. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002, 21(1):11-15.
25. Kong C.S., Beck A.H., Longacre T.A. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol 2010, 34(7):915-926.
26. Han C.P., Lee M.Y., Kok L.F., et al. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Int J Gynecol Pathol 2009, 28(5):489-496.
27. Gien L.T., Beauchemin M.C., Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 2010, 116(1):140-146.
28. Stoler M.H., Mills S.E., Gersell D.J., Walker A.N. Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer. Am J Surg Pathol 1991, 15(1):28-32.
29. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128(4):927-935.
30. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide [computer program]. Version 2. 0 2004, IARC Press, Lyon.
31. Bulk S., Visser O., Rozendaal L., Verheijen R.H., Meijer C.J. Cervical cancer in the Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 2005, 113(6):1005-1009.
32. Liu S., Semenciw R., Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ 2001, 164(8):1151-1152.
33. Smith J.S., Lindsay L., Hoots B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632.
34. Mikuta J.J., Celebre J.A. Adenocarcinoma of the cervix. Obstet Gynecol 1969, 33(6):753-756.
35. Devesa S.S. Descriptive epidemiology of cancer of the uterine cervix. Obstet Gynecol 1984, 63(5):605-612.
36. Horowitz I.R., Jacobson L.P., Zucker P.K., Currie J.L., Rosenshein N.B. Epidemiology of adenocarcinoma of the cervix. Gynecol Oncol 1988, 31(1):25-31.
37. Anderson G.H., Benedet J.L., Le Riche J.C., Matisic J.P., Thompson J.E. Invasive cancer of the cervix in British Columbia: a review of the demography and screening histories of 437 cases seen from 1985-1988. Obstet Gynecol 1992, 80(1):1-4.
38. Anton-Culver H., Bloss J.D., Bringman D., Lee-Feldstein A., DiSaia P., Manetta A. Comparison of adenocarcinoma and squamous cell carcinoma of the uterine cervix: a population-based epidemiologic study. Am J Obstet Gynecol 1992, 166(5):1507-1514.
39. Hepler T.K., Dockerty M.B., Randall L.M. Primary adenocarcinoma of the cervix. Am J Obstet Gynecol 1952, 63(4):800-808.
40. Davis J.R., Moon L.B. Increased incidence of adenocarcinoma of uterine cervix. Obstet Gynecol 1975, 45(1):79-83.
41. Gallup D.G., Abell M.R. Invasive adenocarcinoma of the uterine cervix. Obstet Gynecol 1977, 49(5):596-603.
42. Hildesheim A., Herrero R., Castle P.E., et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 2001, 84(9):1219-1226.
43. Lacey J.V., Frisch M., Brinton L.A., et al. Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control 2001, 12(2):153-161.
44. Munoz N., Franceschi S., Bosetti C., et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002, 359(9312):1093-1101.
45. Lacey J.V., Swanson C.A., Brinton L.A., et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer 2003, 98(4):814-821.
46. Castellsague X., Diaz M., de Sanjose S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006, 98(5):303-315.
47. Smith J.S., Green J., Berrington dG, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003, 361(9364):1159-1167.
48. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55(4):244-265.
49. Schiffman M., Kjaer S.K. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003, 31:14-19.
50. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
51. de Sanjose S., Quint W.G., Alemany L., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
52. Pimenta J., Tous S., Galindo C., de Sanjose S., Alemany L., Bosch B. Estimates of the global burden of cervical adenocarcinoma: impact of HPV vaccination. XIX FIGO World Congress 2009, abstract O138.
53. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324(1):17-27.
54. Clifford G., Franceschi S. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer 2008, 122:1684-1685.
55. Wiley D.J., Douglas J., Beutner K., et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002, 35(Suppl. 2):S210-S224.
56. Schiffman M., Herrero R., Desalle R., et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337(1):76-84.
57. Altekruse S.F., Lacey J.V., Brinton L.A., et al. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol 2003, 188(3):657-663.
58. Wheeler C.M., Hunt W.C., Joste N.E., Key C.R., Quint W.G., Castle P.E. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009, 101(7):475-487.
59. Insinga R.P., Liaw K.L., Johnson L.G., Madeleine M.M. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008, 17(7):1611-1622.
60. Bulk S., Berkhof J., Bulkmans N.W., et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 2006, 94(1):171-175.
61. De Vuyst H., Gichangi P., Estambale B., Njuguna E., Franceschi S., Temmerman M. Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. Int J Cancer 2008, 122(1):244-246.
62. Lai C.H., Huang H.J., Hsueh S., et al. Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer 2007, 120(9):1999-2006.
63. Peedicayil A., Abraham P., Sathish N., et al. Human papillomavirus genotypes associated with cervical neoplasia in India. Int J Gynecol Cancer 2006, 16(4):1591-1595.
64. Tawfik El-Mansi M., Cuschieri K.S., Morris R.G., Williams A.R. Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. Int J Gynecol Cancer 2006, 16(3):1025-1031.
65. Pirog E.C., Kleter B., Olgac S., et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000, 157(4):1055-1062.
66. Vinokurova S., Wentzensen N., Kraus I., et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008, 68(1):307-313.
67. Bulk S., Berkhof J., Rozendaal L., et al. The contribution of HPV18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency. Br J Cancer 2007, 96(8):1234-1236.
68. de Sanjose S., Diaz M., Castellsague X., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7(7):453-459.
69. Ferber M.J., Montoya D.P., Yu C., et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003, 22(24):3813-3820.
70. Liu S.S., Tsang P.C., Chan K.Y., et al. Distribution of six oncogenic types of human papillomavirus and type 16 integration analysis in Chinese women with cervical precancerous lesions and carcinomas. Tumour Biol 2008, 29(2):105-113.
71. Kim M-J, Chung HH, Kim JW, Park N-H, Song Y-S, Kang S-M., The proportion of human papillomavirus type 16 increases along with the grade of abnormal cervical cytology. In: IPvC 2010. Montreal, Canada, 8 February 2010. Abstract.
72. Hudelist G., Manavi M., Pischinger K.I., et al. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 2004, 92(3):873-880.
73. Badaracco G., Venuti A., Sedati A., Marcante M.L. HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness. J Med Virol 2002, 67(4):574-582.
74. Muñoz N., Bosch F.X., Castellsague X., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111(2):278-285.
75. Tjalma W, on behalf of the SCALE study group. Human papillomavirus prevalence and type distribution in cervical adenocarcinoma: results from a multinational epidemiological study in Europe. In: IGCS. 2010. Prague, Czech Republic, 23 October 2010. Abstract.
76. Chen R.J., Lin Y.H., Chen C.A., Huang S.C., Chow S.N., Hsieh C.Y. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 1999, 73(2):184-190.
77. Davy M.L., Dodd T.J., Luke C.G., Roder D.M. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol 2003, 101(1):38-45.
78. Eifel P.J., Burke T.W., Morris M., Smith T.L. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995, 59(1):38-44.
79. Hopkins M.P., Morley G.W. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 1991, 77(6):912-917.
80. Irie T., Kigawa J., Minagawa Y., et al. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol 2000, 26(5):464-467.
81. Kleine W., Rau K., Schwoeorer D., Pfleiderer A. Prognosis of the adenocarcinoma of the cervix uteri: a comparative study. Gynecol Oncol 1989, 35(2):145-149.
82. Lee K.B., Lee J.M., Park C.Y., Lee K.B., Cho H.Y., Ha S.Y. What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. Int J Gynecol Cancer 2006, 16(4):1569-1573.
83. Nakanishi T., Ishikawa H., Suzuki Y., Inoue T., Nakamura S., Kuzuya K. A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2000, 79(2):289-293.
84. Shingleton H.M., Bell M.C., Fremgen A., et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix?. Cancer 1995, 76(10 Suppl.):1948-1955.
85. Quinn M.A., Benedet J.L., Odicino F., et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet 2006, 95(Suppl. 1):S43-S103.
86. Berek J.S., Hacker N.F., Fu Y.S., Sokale J.R., Leuchter R.C., Lagasse L.D. Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival. Obstet Gynecol 1985, 65(1):46-52.
87. Marchiole P., Benchaib M., Buenerd A., Lazlo E., Dargent D., Mathevet P. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH). Gynecol Oncol 2007, 106(1):132-141.
88. Shimada M., Kigawa J., Nishimura R., et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol 2006, 101(2):234-237.
89. Tabata M., Ichinoe K., Sakuragi N., Shiina Y., Yamaguchi T., Mabuchi Y. Incidence of ovarian metastasis in patients with cancer of the uterine cervix. Gynecol Oncol 1987, 28(3):255-261.
90. Eifel P.J., Morris M., Oswald M.J., Wharton J.T., Delclos L. Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer 1990, 65(11):2507-2514.
91. Baalbergen A., Ewing-Graham P.C., Hop W.C., Struijk P., Helmerhorst T.J. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 2004, 92(1):262-267.
92. Peters W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000, 18(8):1606-1613.
93. Burger R.A., Monk B.J., Kurosaki T., et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996, 88(19):1361-1368.
94. Schwartz S.M., Daling J.R., Shera K.A., et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol 2001, 19(7):1906-1915.
95. The American College of Obstetricians and Gynecologists Clinical management guidelines for obstetrician-gynecologists - ACOG Practice Bulletin No. 109: cervical cytology screening. Obstet Gynecol 2009, 114(6):1409-1420.
96. Arbyn M., Herbert A., Schenck U., et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007, 18(3):133-139.
97. Mayor S. NHS cervical screening programme to introduce liquid based cytology. BMJ 2003, 327(7421):948.
98. Noller K.L., Bettes B., Zinberg S., Schulkin J. Cervical cytology screening practices among obstetrician-gynecologists. Obstet Gynecol 2003, 102(2):259-265.
99. Advisory Committee on Cancer Prevention Recommendations on cancer screening in the European Union. Eur J Cancer 2000, 36(12):1473-1478.
100. Anttila A., Ronco G., Clifford G., et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004, 91(5):935-941.
101. Sasieni P., Castanon A., Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009, 339:b2968.
102. Anttila A., Ronco G. Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009, 45(15):2685-2708.
103. Anttila A., von Karsa L., Aasmaa A., et al. Cervical cancer screening policies and coverage in Europe. Eur J Cancer 2009, 45(15):2649-2658.
104. Arbyn M., Anttila A., Jordan J., et al. European guidelines for Quality Assurance in Cervical Cancer Screening. Second edition - summary document. Ann Oncol 2010, 21(3):448-458.
105. Arbyn M., Kyrgiou M., Simoens C., et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008, 337:a1284.
106. Recommended code of practice for laboratories providing a cytopathology service 1997. British Society for Clinical Cytology. Cytopathology 1997, 8(1):1-25.
107. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287(16):2114-2119.
108. Richart R. Natural history of cervical intraepithelial neoplasia. Clin Obstet and Gynecol 1967, 10(4):748-784.
109. World Health Organization. Cervical cancer screening in developing countries; 2002. Available at: [accessed July 2011]. http://whqlibdoc.who.int/publications/2002/9241545720.pdf.
110. International Agency for Research on Cancer Effectiveness of screening in populations. IARC handbooks of cancer prevention volume 10: Cervix cancer Screening 2005, IARC Press, p. 201-25.
111. Kitchener H.C., Almonte M., Thomson C., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009, 10(7):672-682.
112. Arbyn M., Bergeron C., Klinkhamer P., Martin-Hirsch P., Siebers A.G., Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008, 111(1):167-177.
113. Denny L., Kuhn L., De Souza M., Pollack A.E., Dupree W., Wright T.C. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005, 294(17):2173-2181.
114. Anttila A., Kotaniemi-Talonen L., Leinonen M., et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. Br Med J 2010, 340:c1804-c1811.
115. Franco E.L., Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008, 26(Suppl. 1):A16-A23.
116. Kitchener H.C., Almonte M., Wheeler P., et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006, 95(1):56-61.
117. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11(3):249-257.
118. Pak S.C., Martens M., Bekkers R., et al. Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust N Z J Obstet Gynaecol 2007, 47(6):504-507.
119. Sasieni P., Castanon A., Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer 2009, 125(3):525-529.
120. Schorr M. Liquid-based pap test does not improve detection of cervical adenocarcinoma; October 2009. Available at: [accessed July 2011]. http://www.medscape.com/viewarticle/514371.
121. Ashfaq R., Gibbons D., Vela C., Saboorian M.H., Iliya F. ThinPrep Pap Test. Accuracy for glandular disease. Acta Cytol 1999, 43(1):81-85.
122. Bai H., Sung C.J., Steinhoff M.M. ThinPrep Pap Test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol 2000, 23(1):19-22.
123. Mesher D., Szarewski A., Cadman L., et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer 2010, 102(9):1405-1410.
124. Dillner J., Rebolj M., Birembaut P., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ 2008, 337:a1754.
125. Schiffman M, Wacholder S, Glass A, et al., Absolute risks of CIN and cancer in a 16-year prospective study of type-specific HPV infection. In: IPvC. 2010, Montreal, Canada, 3 July 2010. Abstract.
126. Khan M.J., Castle P.E., Lorincz A.T., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97(14):1072-1079.
127. Cuzick J., Arbyn M., Sankaranarayanan R., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26(Suppl. 10):K29-K41.
128. Paavonen J, Naud P, Salmeron J, et al., End-of-study results of PATRICIA: a Phase III efficacy study of HPV-16/18 AS04-adjuvanted vaccine in young women. In: IPvC. 2010. Montreal, Canada, 8 February 2010.
129. EMA. Cervarix Summary of Product Characteristics_Cervarix-EMEA/H/C/000721-II/0018, London, UK; 2011. Available at: [accessed July 2011]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf.
130. Romanowski B, on behalf of the HPV PATRICIA Study Group. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types: end-of-study results. In: IPvC 2010. Montreal, Canada, 8 February 2010.
131. ®: a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 2011, 71(4):465-488.
132. Paavonen J., Naud P., Salmeron J., et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against cervical infection and pre-cancer caused by vaccine and non-vaccine types (PATRICIA): final analysis of a double blind, randomised study in young women. Lancet 2009, 374:301-314.
133. Roteli-Martins CM, Naud P, Borba P, et al., Sustained immunogenicity and efficacy of the HPV 16/18 AS04-adjuvanted vaccine: follow-up to 8.4 years. In: ESPID 2010. Nice, France, 4 May 2010.
134. Munoz N., Kjaer S.K., Sigurdsson K., et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on All HPV-associated genital diseases in young women. J Natl Cancer Inst 2010, 102(5):325-339.
135. Kjaer S.K., Sigurdsson K., Iversen O.E., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2(10):868-878.
136. Brown D.R., Kjaer S.K., Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
137. Centers for Disease Control and Prevention FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the advisory committee on immunization practices (ACIP). MMWR 2010, 59(20):626-629.
138. Badaracco G., Venuti A. Physical status of HPV types 16 and 18 in topographically different areas of genital tumours and in paired tumour-free mucosa. Int J Oncol 2005, 27(1):161-167.
139. Mayrand M.H., Duarte-Franco E., Rodrigues I., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357(16):1579-1588.
140. EMA. Gardasil, Summary of product characteristics gardasil-H-C-703-II-24 19/01/2010, London, UK; 2010. Available at: [accessed July 2011]. http://www.ema.europa.eu/humandocs/PDFs/EPAR/gardasil/emea-combined-h703en.pdf.
141. Goldie S.J., Kim J.J., Kobus K., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007, 25(33):6257-6270.